Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
grapiprant + pembrolizumab
- Development stage
- Unknown
- Lead developer
- ImageneBio
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Grapiprant + pembrolizumab is an investigational combination therapy currently in early-phase clinical trials for advanced or metastatic cancers, specifically microsatellite stable colorectal cancer (MSS CRC) and non-small cell lung cancer (NSCLC) that have progressed following standard therapies. Grapiprant is a small molecule antagonist of the prostaglandin E2 EP4 receptor, intended to reduce inflammation and potentially modulate tumor-promoting effects of prostaglandin signaling. Pembrolizumab is a monoclonal antibody targeting the programmed cell death protein 1 (PD-1) receptor, functioning as a checkpoint inhibitor to enhance the immune system’s recognition and destruction of tumor cells. Together, this combination aims to exploit complementary pathways: direct immunostimulation (pembrolizumab) and inhibition of inflammation-related tumor growth signals (grapiprant) to potentially increase antitumor activity beyond either agent alone[1][2][3][4][5][6][7].
- Other names
- grapiprant + pembrolizumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)PTGER4 (Prostaglandin E2 receptor EP4 subtype)
Beyond the preview
Go deeper on grapiprant + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on grapiprant + pembrolizumab.